Condition: Gastrointestinal Stromal Tumor (GIST) · Solid Tumor, Adult · Sponsor: Ascentage Pharma Group Inc.
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
This description comes directly from the study's public registry record.
Yifan Zhai, M.D., Ph.D. · +86-20-28069260 · yzhai@ascentagepharma.com
Always discuss trial participation with your own doctor first.
| Sun-Yat Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangdong general hospital | Guangzhou, Guangdong, China | Recruiting |
| Henan cancer hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital Tongji Medical College of Huazhong University of Science ang Technology | Wuhan, Hubei, China | Recruiting |
| Chinese PLA general hospital, Beijing, China | Beijing, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03594422